BioSenic provides update regarding current license agreement with Phebra
INSIDE INFORMATION Maintenance of the license isnow subject to the launch of the OATO Phase III before May 2024instead of 31 May 2023 Parties also…
Source: informazione.it
Page 7 - Systemic Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Systemic Sclerosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Systemic Sclerosis Today - Breaking & Trending Today
BioSenic provides update regarding current license agreement with Phebra
INSIDE INFORMATION Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024 instead of 31 May 2023 Parties also currently negotiating a potential renegotiation... | May 29, 2023
Source: marketscreener.com
BioSenic and Pluristyx sign term sheet for market
INSIDE INFORMATION Potential license agreement to produce and commercialize original and transformed ALLOB cells BioSenic to potentially receive royalty...
Source: globenewswire.com
BioSenic provides first quarter 2023 business update
BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023. Key highlights. Strengthening of Executive Committee and Board of Directors with the ...
Source: pharmiweb.com
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Cumberland initiating Phase II FIGHTING FIBROSIS™ clinical trial, Newest program in Cumberland's ifetroban pipeline NASHVILLE, Tenn., May 23, 2023 /PRNewswire/ -- Cumberland... | May 23, 2023
Source: marketscreener.com